Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
暂无分享,去创建一个
Minsong Cao | Matthias Eiber | Johannes Czernin | Ken Herrmann | Narek Shaverdian | Robert E. Reiter | Amar U. Kishan | A. Kishan | J. Hegde | M. Steinberg | C. King | J. Czernin | K. Herrmann | R. Reiter | M. Eiber | M. Rettig | N. Nickols | W. Fendler | J. Calais | M. Cao | Jeremie Calais | Francesco Ceci | Michael L. Steinberg | Wolfgang P. Fendler | Matthew B. Rettig | John V. Hegde | Chris R. King | Nicholas G. Nickols | N. Shaverdian | F. Ceci
[1] Matthias Eiber,et al. 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging , 2018, The Journal of Nuclear Medicine.
[2] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] A. Kishan,et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. , 2017, European urology.
[4] Sylvie Chabaud,et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Pawan K Gupta,et al. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study , 2017, The Journal of Nuclear Medicine.
[6] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.
[7] P. Therasse,et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options , 2018, The Journal of urology.
[10] Steven P. Rowe,et al. PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[11] Issam El-Naqa,et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. , 2009, International journal of radiation oncology, biology, physics.
[12] Charles R. Thomas,et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.
[13] C. Zamboglou,et al. 68Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison , 2016, Theranostics.
[14] M. Schwaiger,et al. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report , 2016, Cancer Imaging.
[15] M. Parmar,et al. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. , 2016, JAMA oncology.
[16] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[17] U. Haberkorn,et al. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[18] H. Sandler,et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. , 2002, International journal of radiation oncology, biology, physics.
[19] T. Eade,et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study , 2018, The Journal of Nuclear Medicine.
[20] T. Holland-Letz,et al. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[21] R. Hicks,et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.
[22] C. Belka,et al. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy , 2017, Radiation Oncology.
[23] Bernd J. Krause,et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[24] A. Kishan,et al. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning , 2017, The Journal of Nuclear Medicine.
[25] T. Shakespeare. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists , 2015, Radiation Oncology.
[26] A. Kural,et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[27] M. Schwaiger,et al. Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study , 2016, Radiation Oncology.
[28] S. Rawal,et al. A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience , 2017, World journal of nuclear medicine.
[29] F. Feng,et al. A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.
[30] U. Haberkorn,et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.
[31] M. Roach,et al. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. , 1998, The cancer journal from Scientific American.
[32] R K Valicenti,et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N. Nickols,et al. The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer , 2018, The Journal of Nuclear Medicine.
[34] H. Hieronymus,et al. Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.
[35] Frederik L. Giesel,et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT , 2017, The Journal of Nuclear Medicine.
[36] Y. Yamada,et al. Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.